SCHEDULE: Kura Oncology Stakeholders File Schedule 13G Amendment

Montanova Capital, Averill Master Fund, and Aaron Cowen have filed an amendment to their Schedule 13G, reporting their beneficial ownership of Kura Oncology, Inc. common stock.

Summary

• This filing is an amendment (No. 6) to a Schedule 13G, dated August 14, 2026, concerning Kura Oncology, Inc. common stock.
• The filing is made jointly by Montanova Capital, LLC, Averill Master Fund, Ltd., and Aaron Cowen.
• Montanova Capital, LLC and Aaron Cowen each report beneficial ownership of 8,575,422 shares, representing 9.7% of the class.
• Averill Master Fund, Ltd. reports beneficial ownership of 7,805,540 shares, representing 8.8% of the class.
• All reported securities are owned by advisory clients of Montanova Capital, LLC, with Averill Master Fund, Ltd. being the only advisory client owning more than 5% of the common stock.
• Aaron Cowen is identified as the control person for Montanova Capital, LLC.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, as it represents a routine amendment to a Schedule 13G, indicating a significant but stable ownership stake rather than a new development.

Positives

• The filing confirms a substantial and consistent ownership stake in Kura Oncology by key entities and individuals.
• The reporting is up-to-date as of June 30, 2026, indicating ongoing compliance and transparency.

Negatives

• No new financial performance data or strategic updates are provided in this filing, as it is purely an ownership disclosure.

Risks

• Concentration of ownership among a few entities could potentially lead to significant influence over corporate decisions, though the filing states the securities were not acquired for the purpose of changing control.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding future performance.

Management Comments

• Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant individual shareholders to report their stakes in public companies. This amendment indicates a continued, substantial investment in Kura Oncology by these parties.

Stakeholder Impact

• Shareholders: The filing provides transparency on significant ownership stakes, which can influence market perception. The disclaimer of beneficial ownership beyond pecuniary interest is a standard legal practice.

Next Steps

• Continued monitoring of Kura Oncology's stock performance and any future filings by these reporting persons.

Key Dates

Keywords

Kura Oncology, Schedule 13G, Beneficial Ownership, Montanova Capital, Averill Master Fund, Aaron Cowen, Amendment, Common Stock